Skin cancer imaging firm Michelson Diagnostics Ltd. (Orpington, England) is expanding its headquarters by leasing a 900 sq-ft. office suite to accommodate the company's growth in manufacturing, R&D and sales administration since its founding in 2006, according to operations director and co-founder Martin Johns. Plans to lease premises in the U.S. in the first half of 2011 are underway as well, he says.
The company attributes its growth to its VivoSight optical coherence tomography (OCT) scanner, which allows dermatologists to see abnormalities that are hidden below the skin surface. This is especially effective in treating non-melanoma skin cancer.
Having earned FDA clearance for clinical use in the U.S. and Europe in January 2010, VivoSight is now being trialed by skin cancer specialists at their clinics. At a time where non-melanoma skin cancer is said to be reaching epidemic proportions with an estimated 3.5 million new cases per year in the U.S., accounting for 4.5% of all Medicare cancer costs and costing the National Health Service (NHS) around £100 million per year in the UK, the VivoSight technology could make a real difference.
Posted by Lee Mather
Follow OptoIQ on your iPhone; download the free app here.
Subscribe now to BioOptics World magazine; it's free!